$2.33
7.37% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US1511901050
Symbol
CELU

Celularity Inc - Ordinary Shares - Class A Stock price

$2.33
+0.81 53.29% 1M
-0.61 20.75% 6M
+0.25 12.02% YTD
-0.81 25.80% 1Y
-72.27 96.88% 3Y
-96.17 97.63% 5Y
-95.67 97.62% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.16 7.37%
ISIN
US1511901050
Symbol
CELU
Sector
Industry

Key metrics

Market capitalization $55.80m
Enterprise Value $123.90m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.29
P/S ratio (TTM) P/S ratio 1.03
P/B ratio (TTM) P/B ratio 5.94
Revenue growth (TTM) Revenue growth 138.11%
Revenue (TTM) Revenue $54.22m
EBIT (operating result TTM) EBIT $-38.55m
Free Cash Flow (TTM) Free Cash Flow $-6.56m
Cash position $740.00k
EPS (TTM) EPS $-2.65
Short interest 29.80%
Show more

Is Celularity Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Celularity Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Celularity Inc - Ordinary Shares - Class A:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Celularity Inc - Ordinary Shares - Class A:

Buy
100%

Financial data from Celularity Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
54 54
138% 138%
100%
- Direct Costs 23 23
10% 10%
42%
31 31
1,318% 1,318%
58%
- Selling and Administrative Expenses 51 51
21% 21%
94%
- Research and Development Expense 11 11
-
21%
-31 -31
54% 54%
-56%
- Depreciation and Amortization 7.92 7.92
15% 15%
15%
EBIT (Operating Income) EBIT -39 -39
50% 50%
-71%
Net Profit -58 -58
71% 71%
-107%

In millions USD.

Don't miss a Thing! We will send you all news about Celularity Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Celularity Inc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
12 days ago
Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year. Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year.
Neutral
GlobeNewsWire
25 days ago
FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company that it has not paid certain fees required by Listing Rule 5250(f) and accordingly the Company will be delisted unless it appeals this determination. The Company's past due fee ba...
Neutral
GlobeNewsWire
about one month ago
Action delays to January 1, 2026, the effective date of a Biden-era Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcers Action delays to January 1, 2026, the effective date of a Biden-era Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcers
More Celularity Inc - Ordinary Shares - Class A News

Company Profile

Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The firms CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. The company is headquartered in Florham Park, NJ.

Head office United States
CEO Robert Gordon
Employees 123
Founded 2016
Website www.celularity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today